2007
Endothelial Activation and Neointimal Hyperplasia: A Double-Edged Sword
Khurana R, Simons M. Endothelial Activation and Neointimal Hyperplasia: A Double-Edged Sword. 2007, 75-84. DOI: 10.1007/1-4020-5955-8_4.Peer-Reviewed Original ResearchActivated endothelial cellsAngiogenic growth factorsNeointimal thickeningEndothelial cellsGrowth factorPercutaneous revascularization proceduresVascular smooth muscle cellsNumerous preclinical modelsVasa vasorum neovascularizationEndothelial cell activationVessel wall remodelingSmooth muscle cellsRole of VEGFPotent angiogenic growth factorRevascularization proceduresStent eraEndothelial activationInflammatory cellsNew capillary growthParacrine sourceVascular responsesNeointimal accumulationEndothelial repairEndovascular proceduresPreclinical models
2000
Therapeutic Angiogenesis
Simons M, Laham R, Post M, Sellke F. Therapeutic Angiogenesis. BioDrugs 2000, 14: 13-20. PMID: 18034552, DOI: 10.2165/00063030-200014010-00002.Peer-Reviewed Original ResearchGrowth factorTherapeutic angiogenesisAdvanced coronary diseaseAdverse effect profileInitial clinical dataRecent clinical experienceBasic fibroblast growth factorQuality of lifeAngiogenic growth factorsFibroblast growth factorCoronary diseaseEffect profileClinical dataPreclinical studiesAnimal modelsClinical experienceNew vasculatureClinical applicationPractical clinical applicationsAngiogenesisBFGFBasic biologyPatientsFactorsSymptoms
1999
Angiogenesis in Cardiovascular Disease
Sellke F, Simons M. Angiogenesis in Cardiovascular Disease. Drugs 1999, 58: 391-396. PMID: 10493268, DOI: 10.2165/00003495-199958030-00001.Peer-Reviewed Original ResearchConceptsInoperable coronary artery diseaseTherapeutic angiogenesisChronic myocardial ischaemiaCoronary artery diseasePreliminary clinical trialsAngiogenic growth factorsMyocardial revascularisationArtery diseaseMyocardial ischaemiaTreatment optionsGrowth factor proteinClinical trialsCardiovascular diseaseMyocardial perfusionProtein administrationAnimal modelsAngiogenic factorsObjective evidenceGrowth factorAngiogenesisPatientsDiseaseAdministrationGene therapyOptimal candidatesTherapeutic Angiogenesis Using Endocardial Approach to Administration: Techniques and Results.
Garcia L, Baim D, Post M, Simons M, Laham R. Therapeutic Angiogenesis Using Endocardial Approach to Administration: Techniques and Results. Current Interventional Cardiology Reports 1999, 1: 222-227. PMID: 11096628.Peer-Reviewed Original ResearchTherapeutic angiogenesisClinical trialsClinical studiesPreclinical studiesSurgical accessSerious systemic adverse eventsSystemic adverse eventsIschemic heart diseaseMost clinical trialsChronic myocardial ischemiaThree-dimensional navigation systemMost preclinical studiesDelivery strategiesAngiogenic growth factorsAdverse eventsLocal therapyGeneral anesthesiaMyocardial ischemiaHeart diseaseFluoroscopic guidanceClinical usefulnessEndocardial approachSystemic recirculationAnimal modelsDelivery catheter
1996
Local Extravascular Growth Factor Delivery in Myocardial Ischemia
Lopez J, Simons M. Local Extravascular Growth Factor Delivery in Myocardial Ischemia. Drug Delivery 1996, 3: 143-147. PMID: 26790909, DOI: 10.3109/10717549609029443.Peer-Reviewed Original ResearchBasic fibroblast growth factorVascular endothelial growth factorIschemic myocardiumGrowth factorCoronary collateral circulationNumber of microvesselsNon-ischemic myocardiumImplantable osmotic pumpMyocardial blood flowPerivascular drug deliveryEndothelial growth factorAngiogenic growth factorsFibroblast growth factorCollateral circulationChronic ischemiaMyocardial performanceMyocardial ischemiaVEGF administrationHeart sectionsBlood flowControl animalsMyocardial perfusionOsmotic pumpControl groupExogenous growth factor delivery